Wednesday, October 15, 2014

Joe Galati, M.D./Harvoni Hepatitis C Therapy New FDA Approval and Patient Information

Joe Galati, M.D.

Harvoni was was approved by the FDA last week, for the treatment of chronic hepatitis C. A fixed dose of Ledipasvir and Sofosbuvir, this is the first once daily, 2-drug therapy. Dr. Galati reviewed the dosing of Harvoni based on the presence or absence of cirrhosis, and whether you have been treated previously.

No comments:

Post a Comment